Cargando…

BCR/ABL1 fluorescence in situ hybridization fusion signals on both copies of chromosome 22 in a Philadelphia-masked chronic myeloid leukemia case: implication for the therapy

The cytogenetic hallmark of Chronic Myeloid Leukemia (CML) is the presence of Philadelphia (Ph) chromosome, which results from a reciprocal translocation t(9;22)(q34;q11). In this report, we describe a CML patient with no evidence of Ph chromosome but trisomy of chromosome 8 as single cytogenetic ab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soriani, Silvia, Guido, Valentina, Bertani, Giambattista, Cesana, Clara, Motta, Valentina, De Canal, Gabriella, De Paoli, Elena, Veronese, Silvio, Bonoldi, Emanuela, Romitti, Lorenza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications, Pavia, Italy 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018256/ https://www.ncbi.nlm.nih.gov/pubmed/33824712 http://dx.doi.org/10.4081/hr.2021.8795

Ejemplares similares

A double‐hit High‐grade B‐cell lymphoma with three‐way translocation t(3;8;14)(q27;q24;q32) involving BCL6, MYC, and IGH
por: De Paoli, Elena, et al.
Publicado: (2018)

FISH mapping of Philadelphia negative BCR/ABL1 positive CML
por: Virgili, Anna, et al.
Publicado: (2008)

Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome
por: de Carvalho, Daiana Landenberger, et al.
Publicado: (2012)

The Functional Interplay Between the t(9;22)-Associated Fusion Proteins BCR/ABL and ABL/BCR in Philadelphia Chromosome-Positive Acute Lymphatic Leukemia
por: Rafiei, Anahita, et al.
Publicado: (2015)

Multiple copies of BCR-ABL fusion gene on two isodicentric Philadelphia chromosomes in an imatinib mesylate-resistant chronic myeloid leukemia patient
por: AL-ACHKAR, WALID, et al.
Publicado: (2013)

Philadelphia Chromosome‐positive Chronic Myelogenous Leukemia with Deleted Fusion of BCR and ABL Genes
por: Ohyashiki, Kazuma, et al.
Publicado: (1990)

Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias
por: Morotti, Alessandro, et al.
Publicado: (2015)

A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review
por: Piedimonte, Monica, et al.
Publicado: (2019)

RUNX1 transactivates BCR‐ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia
por: Masuda, Tatsuya, et al.
Publicado: (2021)

A novel BCR-ABL1 mutation in a patient with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia
por: Vinhas, Raquel, et al.
Publicado: (2018)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

The e1a3 BCR-ABL1 Fusion Transcript in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Langabeer, Stephen E.
Publicado: (2015)

Variant BCR-ABL1 fusion genes in adult Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia
por: Langabeer, Stephen E.
Publicado: (2017)

The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias
por: Carrà, Giovanna, et al.
Publicado: (2016)

Philadelphia Chromosome-positive Acute Myeloid Leukemia With e1a3 BCR-ABL1 Fusion Transcript
por: Sheets, Julia W., et al.
Publicado: (2020)

Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias
por: Smith, Stephanie M., et al.
Publicado: (2021)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells
por: WU, NAN, et al.
Publicado: (2012)

The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias
por: Stella, Stefania, et al.
Publicado: (2019)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients
por: Elias, Marjanu Hikmah, et al.
Publicado: (2012)

Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias
por: Curi, Dany A., et al.
Publicado: (2015)

Multi-Lineage BCR-ABL Expression in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Is Associated With Improved Prognosis but No Specific Molecular Features
por: Nishiwaki, Satoshi, et al.
Publicado: (2020)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Odontogenic fibroma amyloid-variant: a typical case and brief considerations about mimickers
por: de Rezende, Gisele, et al.
Publicado: (2021)

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
por: Deng, Xianming, et al.
Publicado: (2010)

An In-House Method for Molecular Monitoring of BCR-ABL
por: Sercan, Hakkı Ogün, et al.
Publicado: (2012)

Depression of oncogenecity by dephosphorylating and degrading BCR-ABL
por: Gao, Miao, et al.
Publicado: (2016)

Molecular Monitoring in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with the Variant e13a3 BCR-ABL1 Fusion
por: Crampe, Mireille, et al.
Publicado: (2019)

Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Abdelrasoul, Hend, et al.
Publicado: (2020)

Prevalence of atypical BCR-ABL1 transcript types in adult Philadelphia chromosome-positive acute lymphoblastic leukemia: implications for measurable residual disease
por: Bhreathnach, Úna, et al.
Publicado: (2022)

Creation of Philadelphia chromosome by CRISPR/Cas9-mediated double cleavages on BCR and ABL1 genes as a model for initial event in leukemogenesis
por: Tamai, Minori, et al.
Publicado: (2022)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

Role of BCR-ABL1 isoforms on the prognosis of Philadelphia chromosome positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era: A meta-analysis
por: Zhang, Wanhua, et al.
Publicado: (2020)

Jak2/STAT6/c-Myc pathway is vital to the pathogenicity of Philadelphia-positive acute lymphoblastic leukemia caused by P190(BCR-ABL)
por: Qin, Run, et al.
Publicado: (2023)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_302d1iu4834k6gebho5ccsbsbt